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Summary
AIM: Sustained elevation of resting heart rate (RHR) is
thought to promote the initiation and progression of coron-
ary artery disease (CAD). The aim of this paper is to test
the hypothesis whether elevated RHR correlates with the
presence and the extent of CAD in patients evaluated for
CAD.
METHODS AND RESULTS: The association between
RHR and CAD findings and myocardial perfusion SPECT
(MPS) was tested in 1,465 patients. Patients with atrial fib-
rillation, pacemaker rhythm and treatment with negative
chonotropic drugs were excluded. Standard scores for MPS
evaluation were used.
CAD findings of myocardial ischaemia or scar were
present in 408 patients (28%). The prevalence of CAD
finding at MPS was not higher among patients with RHR
above the median value of 79 bpm compared to patients
with lower RHR (28% vs 28%; p = 1.00). The extent of
myocardial ischaemia and scar did not increase with higher
quartiles of RHR. In contrast, the presence of other estab-
lished cardiovascular risk factors such as diabetes, male
gender, more advanced age and presence of CAD symp-
toms such as angina and dyspnoea were independent pre-
dictors of CAD findings (p <0.05 for all).
CONCLUSION: Elevated RHR is not associated with the
presence and the extent of CAD in patients evaluated for
suspected but previously unknown CAD, suggesting that
the impact of a higher RHR on mortality may be linked
with other factors than only CAD itself.
Key words: resting heart rate; coronary artery disease;
myocardial perfusion SPECT
Introduction
There is a growing body of evidence to suggest that sus-
tained elevation of resting heart rate (RHR) is a cardi-
ovascular risk factor [1, 2]. Numerous studies have shown
a relationship between increased RHR and cardiovascular
mortality in the general population [3, 4], and among pa-
tients with various cardiovascular diseases including hy-
pertension [5, 6], coronary artery disease (CAD) [7, 8] and
heart failure [9–11].
The pathophysiological link between increased RHR and
the cardiovascular outcome, however, is not fully under-
stood. Even if suggestive of a causative relation, the associ-
ation between increased RHR and cardiovascular outcome
does not by itself prove causality. Increased RHR may in
fact represent a surrogate marker of the global burden of
risk factors or the presence of more advanced cardiac end-
organ damage [12, 13]. However, an incremental and in-
dependent impact of RHR on prognosis (and sudden cardi-
ac death) was shown by multiple studies [3, 7], and recent
randomised trials provided the evidence that heart rate re-
duction with ivabradine, a selective negative chronotrop-
ic drug, reduced cardiovascular endpoints in patients with
CAD [14] and heart failure [15], suggesting some inde-
pendent mechanism through which elevated RHR may af-
fect cardiovascular risk. In this setting, increased RHR has
been shown to accelerate coronary atherosclerosis in anim-
als and humans [16, 17], to increase risk of rupture of pre-
existing coronary plaques [18], and to trigger myocardial
ischaemia in CAD patients [19, 20].
Based on this, the question is whether increased RHR is
also associated with the presence and the severity of CAD
itself. We therefore sought to assess the association
between RHR and extent of CAD in a population of con-
secutive patients with clinically suspect but previously un-
known CAD referred for myocardial perfusion SPECT
(MPS).
Methods
Study population
All consecutive patients referred for exercise or vasodilator
stress MPS for CAD evaluation at University Hospital
Basel between 2001 and 2005 were considered for this
study (n = 6,719). Patients with known CAD (n = 3,332),
atrial fibrillation or pacemaker rhythm (n = 372), and med-
ical treatment with negative chonotropic drugs, such as
beta-blockers (also in the wash-out phase) and negative
chonotropic calcium channel blockers (n = 1,550), were ex-
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cluded. The final population consisted of 1,465 patients.
Certainly this is a selected and lower risk population than
the average population referred for MPS. Detailed medical
history was collected in all patients.
Myocardial perfusion imaging
All patients underwent routine rest/stress (bicycle er-
gometry or adenosine vasodilator stress) dual isotope
(Tl-201 rest/Tc-99m sestamibi) MPS protocol as previ-
ously described [21, 22]. Rest-single photon emission com-
puted tomography (SPECT) was obtained after administra-
tion of 111 MBq Tl-201. Tl-201 SPECT was performed
10 min after. Stress-SPECT was performed after injection
of a 740 MBq dose of Tc-99m sestamibi was injected.
Post-stress gated SPECT was acquired on average 95–100
min post-stress. SPECT imaging was performed following
standard protocols on triple head cameras (Picker Prism
3000, Philips IRIX). No attenuation or scatter correction
was used. SPECT images were acquired and processed as
previously described [22], with a circular 180° acquisition
(head to head 90°). During imaging, two energy windows
were used for Tl-201, including a 30% window centred
on the 70-keV peak and a 20% window centred on the
167-keV peak. For Tc-99m sestamibi SPECT, a 15% win-
dow centred on the 140-keV peak was used. Semiquantitat-
ive visual interpretation was performed using a 20-segment
model. Each segment was scored using a 5-point scoring
system: 0 = normal, 1 = equivocal, 2 = moderate, 3 = severe
reduction of radioisotope uptake, and 4 = apparent absence
of detectable tracer uptake in a segment. A summed stress
score (SSS) was calculated by adding the scores of the 20
segments of the stress images, and a summed rest score
(SRS) by adding the scores of the 20 segments of the rest
images. To assess defect reversibility, a summed differen-
ce score (SDS) was calculated by subtracting SRS from
SSS, reflecting the severity and the extent of ischaemia.
MPS was considered abnormal in case of scar (SRS ≥4) or
ischaemia (SDS ≥2). For the degree of ischaemia, an SDS
of <2 was considered nonischaemic, SDS 2–4 mildly, SDS
5–8 moderately, SDS 9-12 severely and SDS >12 extens-
ively ischaemic. For the definition of myocardial scar, an
SRS <4 was considered normal, SRS 4–10 moderately and
>10 severely abnormal [23].
Exercise testing protocol
Whenever possible an exercise stress protocol was per-
formed (n = 1,071). RHR, blood pressure and 12-lead ECG
were recorded before exercise. A standardised, sitting,
stepwise and symptom limited bicycle exercise test was
performed to the end points as defined in the exercise test-
ing guidelines [24]. At near-maximal exercise a 740 MBq
dose of Tc-99m sestamibi was injected and exercise was
continued for at least an additional minute after injection.
A 12-lead ECG was continuously recorded during exercise
and recovery. Blood pressure was recorded every minute
during exercise and recovery.
Pharmacological stress test
In patients who were unable to perform an exercise stress
test a pharmacological vasodilator stress protocol was per-
formed (n = 394). RHR, blood pressure and 12-lead ECG
were recorded before pharmacological stress testing. In-
travenous adenosine (140 µg/kg/min.) was infused for 6
minutes, and a 740 MBq dose of 99mTc-sestamibi was in-
jected at the end of the third minute of adenosine infusion
[22]. A 12-lead ECG was continuously recorded during ex-
ercise and recovery. Blood pressure was recorded every
minute during exercise and recovery. Patients were instruc-
ted to refrain from caffeine, and medications such as
aminophylline for 24 hours before MPS.
Definition of the RHR
The RHR was defined on the basis of the 12-lead ECG re-
corded at rest before exercise or vasodilator stress testing
in the sitting position.
Statistics
Numerical data are presented as mean ± standard deviation
or median and interquartile range as appropriate. Categor-
ical data are presented as numbers and percentages. A di-
chotomous division of the population was done on the basis
of the RHR which was below or above to the median
value. Comparison between groups was done with Fisher’s
test for categorical variables, Student’s t-test for numerical
variables with equal distribution and Mann-Whitney-U test
for numerical variables with non-equal distribution. Vari-
ables associated with RHR identified by comparison (p
≤0.1) were included in a multivariate logistic regression
model to identify independent predictors of increased
RHR.
The association between quartiles of the RHR and the
severity of myocardial ischaemia (SDS) and scar (SRS) by
MPS was further assessed by Kruskal-Wallis test.
The comparison between patients with and without CAD
findings at MPS was done by Fisher’s test for categorical
variables and Student’s t-test for numerical variables. Fact-
ors associated with CAD findings at MPS identified by
comparison (p ≤0.1) were included in a multivariable lo-
gistic regression model to identify independent predictors
of CAD findings.
A p-value of ≤0.05 was considered statistically significant.
Analyses were performed using the commercially available
Figure 1
Graphics illustrating the interrelation between the quartiles of
resting heart rate (RHR in bpm) and the severity of myocardial
ischaemia (SDS),
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statistical package (SPSS version 16.0. Inc., Chicago, IL,
USA).
Results
Baseline characteristics and predictors of increased
RHR
The baseline characteristics of the study population are
shown in table 1.
Approximately half of the patients presented with angina
and the global burden of cardiovascular risk factors was
high, as half of the patients had at least 2 cardiovascular
risk factors. The average and median RHR was of 80 bpm.
and 79 bpm. respectively.
As shown in (table 1), patients with an RHR above the
median value of 79 bpm. were younger, more likely to
be female, non-smokers, more frequently had diabetes and
hypercholesterolaemia and were more likely to be on stat-
ins. Of note, that RHR was significantly higher in diabetic
patients than their non-diabetic counterparts, 84 ±14 and
80 ±13 respectively (p <0.001). In female patients the heart
rate was higher than in male patients, 81 ±13 and 80 ±14
respectively (p = 0.02).
In the multivariate analysis younger age, female gender,
hypercholesterolaemia and diabetes were identified as in-
dependent predictors of elevated RHR (table 3). Another
finding of note was that presence of CAD was not a pre-
dictor of elevated heart rate.
Association between RHR and presence and severity of
CAD as assessed by myocardial perfusion SPECT
As shown in (table 2), more than ¼ of this patient popu-
lation without a prior history of CAD did have MPS find-
ings of CAD, including myocardial ischaemia (n = 332;
23%) or myocardial scar (n = 225; 15%). Patients with an
RHR above the median value of 79 bpm did not have a
higher prevalence of CAD findings as compared to patients
with lower RHR. Moreover, increased RHR rate was not
associated with the extent of myocardial ischaemia (SDS)
or myocardial scar (SRS), nor with the global burden of
CAD as assessed with the summed stress score (SSS).
Figure 2
Graphics illustrating the interrelationship between the quartiles of
resting heart rate (RHR in bpm) and the extent of myocardial scar
(SRS) as assessed by MPS. Note that RHR was related neither to
severity of myocardial ischaemia (p = 0.798), nor to the extent of
myocardial scar (p = 0.869).
As shown in figs. 1 and 2, a quartile dependent analysis
confirmed that elevated RHR was not associated with the
severity of myocardial ischaemia (p = 0.798) or scar (p =
0.869) at MPS. On the other hand, patients presenting with
angina (35% vs 22%; p <0.001), dyspnoea (40% vs 26%;
p <0.001), or patients with established cardiovascular risk
factors such as diabetes (34% vs 27%; p = 0.013), active
smoking (32% vs 26%; p = 0.029), male gender (36% vs
18%; p <0.001) and higher age (65 ± 11 vs 60 ± 11; p
<0.001) were more likely to have CAD findings at MPS.
In a multivariate analysis angina, dyspnea, diabetes, male
gender, and higher age turned out to be independent pre-
dictors of CAD findings at MPS but not RHR (table 4).
Discussion
Sustained elevation of RHR is thought to play an important
role in the pathogenesis of atherosclerosis, and heart rate
dependent acceleration of CAD development has been hy-
pothesised as a possible pathomechanism through which
elevated RHR raises cardiovascular morbidity and mortal-
ity [25]. To test the hypothesis that elevated RHR correl-
ates with the presence and the extent of CAD in patients
without a prior history of CAD, we analysed the associ-
ation between RHR and MPS finding of CAD in consecut-
ive patients with suspected CAD evaluated by MPS at our
institution.
The results of this study suggest that there is no association
between elevated RHR and (presence and extent of) CAD
in patients without a prior history of CAD as assessed by
MPS. On the other hand, the presence of other established
cardiovascular risk factors, such as diabetes, male gender
and age were predictors of CAD as assessed by MPS.
Such findings are somewhat in contradiction with the idea
that sustained elevation of RHR may have a detrimental ef-
fect on initiation and progression of coronary atheroscler-
osis. This may in part be because of the different patient
population we used for the analysis. A lot of the data in the
literature has been acquired in animal studies or in congest-
ive heart failure patients [8, 14].
Multiple animal studies showed in fact that increased RHR
may cause dysfunction of the endothelial and vascular
smooth muscle cells via heart rate dependent alterations of
vascular shear stress [26–28]. Additionally, several exper-
imental animal studies consistently showed that heart rate
reduction leads to improvement of the endothelial function
[29, 30]. However, while animal studies provide growing
evidence about the pathophysiologic link between elevated
RHR and atherosclerosis, data on humans are limited and
still inconclusive. While Perski et al. reported that RHR
rate was associated with progression of CAD among sur-
vivors of acute myocardial infarction [31] and Sipahi et al.
showed that beta-blocker treatment was associated with re-
duced progression of CAD [32], Bangalore et al. reported
that treatment with beta-blockers was associated with in-
creased cardiovascular morbidity and mortality in hyper-
tensive patients [33]. This finding may be explained by the
haemodynamic consequences of beta-blocker therapy on
the central circulation, where an augmentation of the cent-
ral aortic systolic blood pressure may be observed [34, 35].
On the other hand, the interpretation of such analyses in
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humans is complicated by the fact that increased RHR in
CAD and hypertensive patients may result from inadequate
adherence to the medical regimen, since patients with high-
er RHR may have discontinued the intake of beta-blockers
and other cardiovascular drugs. Therefore, adherence to the
medical regimen, which is known to be a frequent problem
in cardiovascular patients [36, 37], may represent an im-
portant confounder in the above-mentioned studies.
Table 1: Baseline characteristics and univariable predictors of increased RHR.
Overall (n = 1,465) Resting HR <79 bpm (n = 736) Resting HR ≥79 bpm (n = 729) p-value
Age 61.8 ± 11.4 62.7 ± 11.2 60.9 ± 11.5 0.002
Male gender 845 (58) 449 (61) 396 (54) 0.011
BMI, kg/m2 27.2 ± 4.9 27.0 ± 4.6 27.4 ± 5.2 0.117
Heart rate, bpm 80±14 69 ± 7 91 ± 9 <0.001
Symptoms
Angina 689 (47) 353 (48) 336 (46) 0.496
Dyspnoea 191 (13) 91 (12) 100 (14) 0.485
Risk factors
Hypertension 743 (51) 358 (48) 385 (54) 0.117
Diabetes 250 (17) 97 (13) 153 (21) <0.001
Active smoking 421 (29) 231 (31) 190 (26) 0.028
Hypercholesterolaemia 555 (38) 251 (34) 302 (42) 0.003
Family history 393 (27) 188 (26) 205 (28) 0.288
≥2 risk factors 733 (50) 347 (47) 386 (53) 0.028
Medication
Aspirin 624 (43) 320 (44) 304 (42) 0.493
ACE-inhibitors 255 (17) 119 (16) 136 (19) 0.215
Angiotensin receptor blockers 266 (18) 121 (17) 145 (20) 0.091
Statins 318 (22) 144 (20) 174 (24) 0.049
Calcium channel blockers* 212 (15) 113 (15) 99 (14) 0.335
Diuretics 324 (22) 148 (20) 176 (24) 0.068
Data of continuous variables are given as mean ± standard deviation.
Data of categorical variables are given as numbers (percentage).
BMI = body mass index; ACE = angiotensin converting enzyme. * Nifedipin or amlodipine type calcium channel blockers.
Table 2: Results of the SPECT study.
Overall (n = 1,465) Resting HR <79 bpm (n = 736) Resting HR >79 bpm (n = 729) p-value
Physical stress testing 1,071 (73) 493 (70) 578 (79) 0.02
LVEF 58 ± 11 58 ± 11 58 ± 12 0.238
SRS 0 (0–2) 0 (0–2) 0 (0–2) 0.752
SSS 0 (0–4) 0 (0–4) 0 (0–4) 0.486
SDS 0 (0–0) 0 (0–1) 0 (0–0) 0.278
Ischaemia 332 (23) 174 (24) 158 (22) 0.383
Scar 225 (15) 111 (15) 114 (16) 0.772
CAD findings 409 (28) 205 (28) 204 (28) 1.000
Data of continuous variables are given as mean ± standard deviation or median (interquartile ranges) as appropriate.
Data of categorical variables are gives as numbers (percentage).
LVEF = left ventricular ejection fraction; SRS = summed rest score; SSS = summed stress score; SDS = summed difference score.
Ischaemia: SDS ≥2; Scar: SRS ≥4; CAD findings: presence of scar or ischemia at MPS.
Table 3: Independent predictors of elevated RHR.
OR 95%-CI p-value
Age, per year 0.982 0.972–0.991 <0.001
Female gender 1.369 1.102–1.702 0.005
Hypercholesterolaemia 1.307 1.010–1.702 0.042
Diabetes 1.718 1.287–2.298 <0.001
OR = odds ratio; CI = confidence interval.
Table 4: Independent clinical predictors of CAD findings at MPS.
OR 95%-CI p-value
Angina 2.075 1.616–2.659 <0.001
Dyspnoea 1.678 1.192–2.358 0.003
Diabetes 1.379 1.012–1.879 0.042
Male gender 3.311 2.518–4.376 <0.001
Age, per year 1.043 1.031–1.055 <0.001
RHR, per beat 1.007 0.998–1.016 0.14
OR = odds ratio; CI = confidence interval.
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Considering that the association between RHR and the ex-
tent of CAD has not previously been well established in
humans, the results of the current study provide important
new insight in this context. Of course, as opposed to dia-
gnostic techniques such as coronary angiography and in-
travascular ultrasonography, MPS does not provide inform-
ation about the anatomy, morphology and function of the
coronary vessels. However, MPS findings of ischaemia are
known to correlate with the morphological extent of CAD
and, even more, the prognostic value of MPS is superior to
that provided by coronary angiography [38].
Hence the results of the current study may question the
concept that initiation and progression of atherosclerosis
and CAD is responsible for the increased cardiovascular
and non-cardiovascular mortality related to sustained elev-
ation of RHR in humans. In this context, other mechanisms
such as reduced myocardial blood supply in patients with
haemodynamically significant coronary stenosis related to
increased heart rate and consequent shortening of the dia-
stolic phase [19, 20], triggering of cardiac arrhythmias [39,
40], altered myocardial energetics [41], or consequences
of autonomic neuropathy, especially in diabetics [42]. It is
worthy of note that a higher RHR per se is not proof of
autonomic neuropathy.
However, autonomic neuropathy may dominate the patho-
physiological scenario linking sustained elevation of RHR
and cardiovascular outcomes. Of note, cardiac autonomic
neuropathy is linked with increased mortality in diabetic
patients [43].
Limitations
The results of the current study only apply to this “selec-
ted” population of patients without a prior history of CAD
referred for MPS at the discretion of their treating physi-
cian. Here too, patients with atrial fibrillation, pacemaker
rhythm, and intake of drugs with negative chronotropic ef-
fects were excluded. Hence some selection bias may have
affected the results of this study. Importantly, patients with
known CAD were excluded because the majority were on
beta-blocker treatment and, even if anti-anginal drugs were
discontinued whenever possible, a sustained effect on RHR
has to be assumed.
Coronary angiography is known to be more sensitive than
MPS in detecting an early manifestation of CAD such as
coronary plaques without haemodynamically relevant sten-
osis. Thus we cannot exclude that the results would be
different if coronary angiography were used to define the
presence and extent of CAD.
RHR was not measured according to a pre-defined stand-
ard, as recommended by the European Society of Hyper-
tension, meaning that the RHR was not measured after a
resting period of 5 minutes and in sitting position in all
patients [44, 45]. However, RHR was assessed by 12-lead
ECG, thus ensuring a very precise measurement. In general
a higher RHR than those measured according to the above-
mentioned guidelines has to be expected, since RHR meas-
urements are affected by a number of confounders, in-
cluding psychic stimuli, body position, and environmental
factors [45]. We feel that the method with which RHR
was assessed in the current study does not influence the
paper’s conclusions because we compared patient groups
with lower versus higher heart rates as dichotomised by the
median RHR of the population.
Conclusions
Elevated RHR is not associated with the presence and ex-
tent of CAD in patients evaluated for suspected but pre-
viously unknown CAD. This observation suggests that the
impact of a higher RHR on mortality may be linked with
other factors than only CAD itself.
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Figures (large format)
Figure 1
Graphics illustrating the interrelation between the quartiles of resting heart rate (RHR in bpm) and the severity of myocardial ischaemia (SDS),
Figure 2
Graphics illustrating the interrelationship between the quartiles of resting heart rate (RHR in bpm) and the extent of myocardial scar (SRS)
as assessed by MPS. Note that RHR was related neither to severity of myocardial ischaemia (p = 0.798), nor to the extent of myocardial scar
(p = 0.869).
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